We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

Allergy Therapeutics

Record revenues demonstrate resilience of operations

Update | 03 March 2021

MaxCyte

Better visibility brings future into focus

Update | 08 February 2021

MaxCyte

US institutional private placing raises £40m

Lighthouse | 05 February 2021

Scancell

H121 results highlight shift to delivery and execution

Lighthouse | 29 January 2021

Redx Pharma

FY20 results highlight extent of progress made

Update | 27 January 2021

Allergy Therapeutics

Robust growth, pipeline progress, and cash position

Update | 13 January 2021

Allergy Therapeutics

Imperial peanut allergy biomarker study underway

Lighthouse | 05 January 2021

Hutchison China MediTech

China approval clears Sulanda in epNET

Update | 04 January 2021

Redx Pharma

Funding secured to support next chapter of growth

Update | 04 January 2021

Mereo BioPharma

Setrusumab partnered with Ultragenyx

Lighthouse | 18 December 2020
1 2 3 4 5 6 7 8 9 10 >
241 results found.